Search the PBPK Model Repository

Quickly find freely available drug and population models in our PBPK model repository.

The models provided have been collated from published examples which authors have shared in our Published Model Collection or developed as part of various global health projects in our Global Health Collection. This search facility searches both model collections simultaneously.

To contribute published user compound and/or population files, upload your files here: Upload Model Files

Searching Tips

You can use a * character as a wildcard at the end of a alphanumeric search term. The search term must start with at least one character before the wildcard. E.g., Rifam* will get you “Rifampicin” and “Rifampin”.
You can also use a * character as a wildcard in the middle of a alphanumeric search term. The search term must still start with at least one character before the wildcard. E.g., Rif*in will also get you “Rifampicin” and “Rifampin” .
You can also use a * character as a wildcard at the start of a alphanumeric search term. However you must use forward slashes to delimit the search term and use a point before the wildcard. E.g., /.*picin/ will only get you “Rifampicin”.

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Found 95 Matches

Benzylpenicillin_RES_V20R1_Simcyp_20210512

Model Files Publication

The RES-Benzylpenicillin file was primarily developed as a substrate of renal OAT3 transport. This document provides: 1. Examples of model performance 2. A summary of the key pharmacokinetic features of benzylpenicillin considered within the model.

Search Score: 1

Darolutamide_RES_V21R1_Simcyp_20230615

Model Files Publication

The RES-Darolutamide_V21 model has been developed primarily as inhibitor of hepatic OATP1B1 and OATP1B3, and intestinal BCRP using the New GI physiology in Simcyp V21 with altered GI tract population inputs that became default in V22. Darolutamide shows dose proportional PK between 100 to 700 mg BID. It is a BSCII compound, where the metabolite is a potent BCRP-inhibitor too. Darolutamide is possibly a weak CYP3A inducer in the clinic. The back-conversion of Keto-darolutamide to Darolutamide is efficiently catalyzed via cytosolic AKR1C3 (in vitro). This back-conversion is also observed in incubations of feces under anaerobic conditions (in vitro). In the compound fit-for-purpose compound file, the back-conversion was fixed to recover the concentration time profile for the 600 mg BID as this was the dose for the reported Rosuvastatin DDI. Note that two workspaces need to be run to simulate the Darolutamide DDI and then the results have to be combined. This is due to having to switch the position of Darolutamide and rosuvastatin (limitations on functionality on inhibitory metabolite in the Simcyp Simulator currently).

Search Score: 1

Mefloquine

Model Files Publication

Brand Name(s) include: Lariam, Mephaquin, Mefliam

Disease: Malaria

Drug Class: Antimalarials

Date Updated: November 2021

The model at-a-glance

Absorption Model	First-Order
Volume of Distribution	Full PBPK (Method 2)
Route of Elimination	CYP3A4 (fm =100); renal clearance (fe = 0.05)
Perpetrator DDI	CYP2C9 Inhibitor CYP2D6 Inhibitor CYP3A4 Inhibitor
Validation	Six clinical studies describing single and multiple dose exposure of mefloquine were used the verify the PBPK model. Most of the studies (83%) were within 1.5-fold, with all simulations falling within 2-fold of the observed values. Two clinical DDI studies where mefloquine was the victim of a CYP3A4-mediated DDI were accurately recovered using the PBPK model.
Limitations	Only profiles of plasma concentrations assessed, many studies report blood concentrations Mefloquine has significant uptake into erythrocytes and haematocrit levels typically not reported Could be important in disease population (Possible time-varying B/P for Malaria patients?) Cmax for doses > 750 mg over predicted fa possibly decreases with dose, more data needed to fully determine the cause Most literature data extracted from graphs of mean data, difficulty determining accurate early time points due to poor image quality Verification needed for perpetrator DDI assessment as literature data is unavailable at this time
Updates in V19	Updated in vitrodata fu_p: 0.016 -> 0.015 B:P ratio 1.7 -> 1.1 and subsequent re-calculation of CLint using the retrograde approach Converted model to full PBPK distribution model with Vss predicted through Method 2 Sensitivity analysis of ka

Search Score: 1

Carboxyprimaquine

Model Files Publication

Disease: Malaria

Drug Class: Antimalarials

Date Updated: March 2022

Related Files: Primaquine (parent)

The model at-a-glance

Absorption Model	N/A
Volume of Distribution	Full PBPK (Method 2)
Route of Elimination	Formed from primaquine by MAO. This is entered as ‘user-UGT’ as a surrogate within the simulator Pathway of elimination is not defined; elimination is assigned as IV clearance that was manually optimized to fit the clinical data
Perpetrator DDI	None
Validation	Six clinical studies describing single and multiple dose exposure of carboxyprimaquine were used to verify the PBPK model. The AUC for all verification studies were within 1.5-fold of the observed values.
Limitations	Clinical data for carboxyprimaquine is highly variable
Updates in V19	Converted from minimal PBPK model to full PBPK model

Search Score: 1

Search the PBPK Model Repository

Searching Tips

Benzylpenicillin_RES_V20R1_Simcyp_20210512

Darolutamide_RES_V21R1_Simcyp_20230615

Mefloquine

The model at-a-glance

Carboxyprimaquine

The model at-a-glance

Your Privacy